Patent · US Active

Salts of Dasatinib in crystalline form

US9556164B2 · kind B2 · utility

7Cited by

8References

19Claims

0Family size

Assignee

BASF SE

Inventors

Andreas Hafner · Gelterkinden, CH
Fritz Blatter · Reinach, CH
Martin Szelagiewicz · Münchenstein, CH
Bernd Siebenhaar · Kandern, DE
Tiziana Chiodo · Mannheim, DE
Tobias Hintermann · Therwil, CH
Beate Salvador · Ellerstadt, DE
Marcus Vossen · Schifferstadt, DE

Key dates

Filing date	Jul 22, 2014
Grant date	Jan 31, 2017
Priority date	—
Expiry date	Jul 22, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1,and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.